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Gastroenteropancreatic neuroendo-
crine tumors (GEP-NETs) are a  large 
and very diverse group of neoplasms. 
Clinical presentation of NETs depends 
on the site of the primary tumor and 
whether the tumor is functioning 
(i.e., secreting peptides or neuroam-
ines that produce symptoms). The 
diagnosis of GEP-NET is further com-
plicated by symptomatic differences 
that occur depending on the type of 
secreted peptide or neuroamine. Due 
to their heterogeneity and unique 
characteristics, early diagnosis of 
GEP-NETs is difficult, which increases 
the likelihood of metastatic disease 
and reduces the scope of therapeutic 
possibilities. Thus, a multidisciplinary 
approach for the treatment of GEP-
NETs is necessary. This review is the 
result of presentations that were de-
livered during an expert meeting on 
the treatment of GEP-NETs supported 
by Ipsen. We summarize the current 
knowledge on the epidemiology, in-
cidence, diagnosis, and treatment of 
GEP-NETs. We examined the role of 
the somatostatin analog (SSA) lan-
reotide and the impact of the data 
from the recently published, random-
ized, double-blind, placebo-controlled 
CLARINET study (Controlled study of 
Lanreotide Antiproliferative Response 
In Neuroendocrine Tumors) on dis-
ease management. We also review 
the recent treatment options and rec-
ommendations for GEP-NETs.
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Epidemiology and prevalence of neuroendocrine tumors
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a hetero-
geneous group of neoplasms arising from highly specialized cells of the dif-
fuse endocrine system [1]. The characteristic feature of NETs is their ability 
to synthesize, store, and secrete peptides, hormones, and neuroamines. Ac-
cording to global statistics reported in 2010, the average prevalence of NETs 
is 5.25 cases per 100 000 population per year, with the risk increasing after 
50 years of age [2]. GEP tumors account for 70% of all NETs and about 2% of 
all gastrointestinal system tumors [1]. 
GEP-NET primary lesions are most commonly localized in the gastric mu-
cosa, the small and large intestine, the rectum, or the pancreas [1]. Accord-
ing to the American Surveillance Epidemiology and End Results (SEER) da-
tabase, the incidence per year is 0.95 per 100 000 for small intestinal NETs 
(previously called classical carcinoids), 0.86 per 100 000 for rectal NETs, 0.32 
per 100 000 for pancreatic NETs, and 0.30 per 100 000 for gastric NETs [2]. 
The number of NETs is greater than the number of pancreatic and gastric 
tumors combined [2]. 
The incidence of NETs in the United States increased from 1.09 per 
100 000 in 1973 to 5.25 per 100 000 in 2004 [3]. This increasing trend was 
also noted in Poland, where pancreatic NETs are most common (~30% of 
all NET patients have pancreatic NETs according to the patient database of 
the Department of Endocrinology of Jagiellonian University Medical College 
in Cracow, Poland). However, small intestinal and rectal NETs are now con-
sidered the fastest growing group of NETs [3]. The increasing incidence of 
GEP-NETs has created the need for a broad and holistic overview of the pa-
tient pathway, from diagnosis through to treatment, as highly specialized 
procedures are required for very differentiated groups of patients.
Diagnosis of gastroenteropancreatic neuroendocrine tumors
Clinical presentation of NETs depends on the site of the primary tumor, 
and whether the tumor is functioning (i.e., secreting peptides or neuroam-
ines that produce symptoms) or not. The diagnosis of GEP-NET is further 
complicated by symptomatic differences that occur depending on the type 
of secreted peptide or neuroamine. Most GEP-NETs are non-functioning 
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(they constitute 70% of all NETs in Poland according to 
our data) and present quite late, with symptoms of mass 
effects or distant (usually hepatic) metastases, or both. 
Nonspecific symptoms of the disease are usually misdiag-
nosed as more common disorders, including food allergy, 
menopause, asthma, irritable bowel syndrome, arthritis, 
thyrotoxicosis, and anxiety [4]. In more than 60% of pa-
tients, the disease is diagnosed at an advanced stage [5]. 
As delayed or erroneous diagnosis of GEP-NETs is common 
(5–7 years on average), the probability of metastatic dis-
ease is increased, which reduces the scope of therapeutic 
possibilities, especially targeted therapy [5].
Gastric neuroendocrine neoplasms typically present as 
multiple, small, localized tumors and are associated with 
hypergastrinemia, either secondary to chronic atrophic 
gastritis or as part of Zollinger-Ellison syndrome. Most du-
odenal NETs will secrete gastrin and cause Zollinger-Elli-
son syndrome [5]. While gastric NETs typically have low 
malignant potential (less than 2–5% metastasize), large 
solitary gastric NETs do often metastasize [5]. Colon NETs, 
which are often large tumors, have the worst prognosis of 
all GEP NETs, mainly due to being diagnosed at the stage 
of liver metastases. Alternatively, small non-functioning 
rectal NETs are usually diagnosed incidentally during rou-
tine colonoscopy [5].
For pancreatic NETs, about 40% are non-functioning 
and about 50% have hepatic metastases at diagnosis [5]. 
Functioning pancreatic NETs may secrete several peptide 
hormones, leading to diverse symptoms. For example, in-
sulinomas are typically small functioning NETs that cause 
hypoglycemia, glucagonomas are often larger tumors that 
cause diabetes and a characteristic rash (necrolytic migra-
tory erythema), and VIPomas (large tumors originating 
from the pancreatic cells that produce vasoactive intesti-
nal peptide [VIP]) are associated with severe diarrhea [5]. 
In patients with NETs (which originate in the distal jeju-
num and ileum and commonly metastasize to the liver), 
serotonin, tachykinins, and other bioactive substances 
reach the circulation and may cause carcinoid syndrome 
in cases of liver metastasis. Carcinoid syndrome is char-
acterized by cutaneous flushing, diarrhea, and abdominal 
pain and occurs in about 18% of patients with jejunoileal 
enterochromaffin tumors. Moreover, liver involvement 
from metastatic disease might cause symptoms related to 
tumor bulk and capsular invasion [5].
Apart from diagnostic difficulties resulting from the di-
verse nature of GEP-NETs originating from different sites, 
other factors can contribute to the delay in diagnosis, as 
indicated by Modlin et al. [4]. These factors include a defi-
ciency in physicians’ knowledge and training, general as-
sumptions that these tumors are very rare and benign, as 
well as poor public education [4]. The best solution to over-
come these obstacles and improve care and management 
of GEP-NET patients is to implement a multidisciplinary 
approach [4, 6]. 
A multidisciplinary model assumes that patient care 
is delivered by a group of healthcare professionals repre-
senting different fields of medical sciences. Many benefits 
of a multidisciplinary healthcare model have been proven 
for other types of tumors, including improvements in di-
agnosis, consistent use of diagnostic tests, improvements 
in disease staging, decreased time between diagnosis and 
the start of therapy, and more common selection of evi-
dence-based treatment [6]. It was also noted that centers 
that implemented a multidisciplinary approach recorded 
improved patient survival [6, 7]. Indeed, both the Ameri-
can Society of Clinical Oncology (ASCO) and the European 
Society for Medical Oncology (ESMO) state that a multidis-
ciplinary care model should be a standard for all oncolog-
ical patients [8]. During diagnosis and in the early stages 
of therapy, the most significant work is performed by the 
surgeon, endocrinologist, radiologist, pathologist, gastro-
enterologist, and oncologist [6]. 
According to experts, in referral-based healthcare sys-
tems such as that currently used in Poland, it is challeng-
ing for a physician to suspect or diagnose NET and refer 
the patient for further diagnostics and therapy in a highly 
specialized unit. As stated by the experts at the meeting, 
the diagnosis of a GEP-NET is most commonly made by 
a surgeon or histopathologist. Then, the patient is referred 
for further diagnosis and treatment by an endocrinologist 
or oncologist. Polish patients are now referred to NET-fo-
cused medical centers most commonly with a diagnosis 
that is made either (a) in surgery departments or surgical 
clinics (they constitute the main group of NET patients), 
(b) on the basis of radiological imaging, or (c) by general 
practitioners on the basis of elevated levels of 5-hydroxy-
indoleacetic acid (5OHIAA; for these patients the diagno-
sis is very often erroneous).
The key data necessary to make a proper and compre-
hensive diagnosis of NET according to the experts and Pol-
ish guidelines [1] are:
• assessment of the disease stage (local/metastatic/
non-resectable),
• visualization of the primary tumor and metastases 
(if applicable),
• presence of liver metastases,
• size of the tumors,
• assessment of secreted hormones.
One sensitive (but non-specific) diagnostic tool is 
a screening laboratory test for serum chromogranin 
A (CgA); however, false positive results can be achieved 
in many other medical disorders, such as lung, pancreas 
and prostate cancer, renal insufficiency, atrophic gastritis, 
and administration of some medicines (e.g., proton pump 
inhibitors, histamine receptor antagonists, and corticoste-
roids).
Improvements of the GEP-NET patient pathway should 
result in better prognosis and prolonging patients’ lives. 
The overall survival varies among patients with different 
types of GEP-NETs. For example, the 5-year survival rate 
for pancreatic NET varies from 97% for benign insulino-
mas to 30% for those that are non-functioning and clini-
cally silent [5]. Overall 5-year survival is also estimated to 
be 60–100% for localized disease, 40% for regional, 25% 
for metastatic, and 80% for all stages of pancreatic tu-
mors [2]. The overall 5-year survival for NETs of the small 
intestine is about 60%. The mean overall survival for all 
GEP-NET is about 33 months [5]. Patients with high-grade, 
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poorly differentiated neuroendocrine carcinomas present 
a median survival of only 10 months [2]. 
Treatment of gastroenteropancreatic 
neuroendocrine tumors
A multidisciplinary team of diverse specialists who 
work together is important both for accurate diagnosis 
and therapeutic efficacy in GEP-NET patients. During the 
next stages of treatment, the optimal management of 
a GEP-NET patient is provided mainly by endocrinologists, 
nuclear physicians, oncologists, interventional radiolo-
gists, gastroenterologists, specialized nurses, geneticists, 
and cardiologists, among others [6]. All these specialists 
should be involved in order to provide optimal patient care, 
stop the development and growth of the tumor, as well as 
to modulate hormone secretion to decrease clinical symp-
toms and improve quality of life (QoL). During different 
phases of the treatment process, the team should consist 
of appropriate professionals reflecting the current needs 
of the patient. Moreover, the treatment should be highly 
individualized based on the tumor burden and symptoms. 
The best therapeutic choice depends on whether the main 
aim of treatment is to slow tumor progression or amelio-
rate symptoms by inhibition of the secretion of bioactive 
agents [5]. 
There are two types of recommended therapy models: 
Tumor Boards and Multidisciplinary Teams [9]. The Tumor 
Board consists of a group of healthcare specialists that 
analyze every GEP-NET case in a complex way. Meetings 
of a Tumor Board are held at different time intervals for 
specific patients, without the patient or his representative. 
After a consultation with the Tumor Board, the main physi-
cian makes a final decision about treatment. On the other 
hand, the Multidisciplinary Team is a more dynamic struc-
ture. The experts of a Multidisciplinary Team collaborate 
throughout the entire time care is provided to a patient, 
and the patient is invited to participate in the treatment 
planning process. The Multidisciplinary Team is required 
to make clinical decisions on the basis of their knowledge, 
experience, and actual evidence-based research [9].
In addition to the medical treatment (including surgi-
cal and pharmacological treatment, as well as radio- and 
chemotherapy), psychosocial support for the patient, their 
caregivers, and their families should be provided. The role 
of associations for patients with NETs, online support 
groups, and educational programs should not be under-
estimated.
Surgical treatment for gastroenteropancreatic 
neuroendocrine tumors
Surgery is essential in many phases of GEP-NET man-
agement, and it remains the primary method of treatment 
in patients with limited disease with the intention to cure. 
For patients with more advanced disease, cytoreductive 
surgery is recommended for palliation and increased sur-
vival. In cases of non-resectable tumors, surgery can obvi-
ate bowel obstruction from small-bowel mesenteric fibro-
sis related to small-bowel NETs [3]. The main limitation of 
surgery is that more than 80% of patients have liver or 
lymph node metastases [3]. Most patients (90–100%) with 
insulinomas have enucleation and occasionally resection, 
and 85–95% of them are cured. About 45–65% of patients 
with gastrinomas are free of tumors after surgery, and 
35% remain so at 5 years [3]. For gastrin-secreting tumors, 
60–80% are duodenal and therefore routine duodenotomy 
and duodenal transillumination are important. Standard 
surgery for duodenal NET is enucleation or local resection.
Other pancreatic NETs and small bowel and colon NETs 
are usually diagnosed at the stage of extensive metastatic 
disease, limiting the likelihood of curative surgery. Howev-
er, resection to avoid obstruction or bleeding may be per-
formed in such cases [3]. Primary gastrointestinal NETs of 
the stomach, duodenum, or rectum are typically smaller 
than 1 cm in diameter and can be cured endoscopically 
if they are non-invasive; otherwise, en bloc resection is 
done. According to global statistics, hepatic metastases 
are present in about 50–75% of small-bowel NETs, 5–70% 
of foregut NETs and 14% of hindgut NETs. For pancreat-
ic NETs, 30–85% of cases give hepatic metastasis and are 
only completely resectable in 7–15% of patients [3].
Chemotherapy and gastroenteropancreatic 
neuroendocrine tumors
Chemotherapy is recommended to treat poorly differ-
entiated or rapidly progressive grade 3 tumors. Etoposide 
plus cisplatin is effective in 40–70% of patients with poorly 
differentiated tumors progressing after surgery. Streptozo-
tocin with fluorouracil or doxorubicin can be used to treat 
patients with malignant endocrine pancreatic tumors, 
with response rates of 30–50% [1, 2, 5, 10]. 
Peptide receptor radionuclide therapy and 
gastroenteropancreatic neuroendocrine tumors
NETs are considered to demonstrate low radiosensitiv-
ity; nevertheless, teleradiotherapy can be used as pallia-
tion for these diseases [1]. In radiotherapy of GEP-NETs, so-
matostatin analogs (SSAs) radiolabelled with 177Lu and 90Y 
are used for the treatment of patients with unresectable 
GEP-NET. The inclusion criterion for peptide receptor radio-
nuclide therapy (PRRT) is high expression of somatostatin 
receptors (SSTRs), confirmed in somatostatin receptor im-
aging (SRI) investigation. The aim of PRRT is to decrease 
the tumor mass. Following PRRT, complete or partial remis-
sion can be achieved in 8–46% of patients, with a mean 
progression-free survival of 25–36 months [1]. 
The first evidence to prove PRRT efficacy came from 
the single-center phase I and II studies by Kwekkeboom 
et al. in 2008 [11]. Five hundred and four patients included 
in this study were treated with a mean number of 4 cycles 
with 177Lu-DOTA-TATE administered once per 6–10 weeks 
[11]. The group of patients showing tumor response to the 
treatment was characterized by a higher overall survival 
(p < 0.001) compared to those who experienced disease 
progression during treatment [11]. In 2014, Delpassand 
et al. reported increased survival in patients treated with 
4 cycles of 177Lu-DOTA-TATE PRRT compared to patients 
treated with < 4 cycles [12]. Progression of the disease 
was observed in 28% of patients, partial tumor regression 
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was seen in 28%, minimal regression occurred in 3%, and 
disease stabilization was achieved in 41% of patients [12]. 
Two other studies have assessed the use of 90Y-DOTA-TOC 
PRRT [13, 14]. Bushnell et al. investigated the efficacy of 
three cycles of 90Y-DOTA-TOC treatment in 90 NET patients 
and found that the tumor responded to the treatment or 
the disease was stabilized in 74% of patients [13]. In ad-
dition, a multicenter study on 1109 metastasized NET pa-
tients treated with two cycles of 90Y-DOTA-TOC showed 
that a clinical response to treatment was observed in 30% 
of patients, and the disease was stabilized in 5% of pa-
tients [14]. A summary of the studies concerning efficacy 
and safety of PRRT in patients with metastatic NETs is pre-
sented in Table 1.
According to the new European Neuroendocrine Tumor 
Society (ENETS) 2016 Guidelines [15], PRRT is recommended 
in midgut NETs as the second line therapy after failure of 
SSAs if the general requirements to apply PRRT are fulfilled 
or as the third line therapy after failure of medical treat-
ment with everolimus. These recommendations are based 
on the results of the NETTER-1 trial, as well as on cumulative 
data from trials conducted over the past 15 years [15]. PRRT 
is also recommended in the treatment of grade 1 and grade 
2 NETs after failure of medical therapy including SSAs, che-
motherapy, or novel targeted drugs. However, potential in-
creasing toxicity, e.g., after prior chemotherapy or targeted 
therapy, must be considered, which requires close surveil-
lance and might justify earlier use of PRRT in selected pa-
tients. The last recommended use for PRRT is in advanced 
NETs after failure of medical treatment [15]. The safety and 
efficacy of PRRT among patients with NETs is currently be-
ing studied in ongoing trials including the following aspects 
of the therapy: personalization of the dosages [16, 17], or 
additional treatment (e.g. capecitabine) [18].
Somatostatin analog treatment in 
gastroenteropancreatic neuroendocrine tumors
The gold standard of pharmacological treatment of 
functional and non-functional GEP-NETs is therapy with 
somatostatin analogs (SSAs) [1]. SSAs not only decrease 
hormone and peptide secretion, but also inhibit disease 
progression [1]. The most used SSAs, lanreotide and oct-
reotide, were developed by modifying the natural soma-
tostatin molecule to achieve a more stable form with the 
highest selectivity for the SSTR type 2 [1]. 
SSAs are effective for syndrome control in functional 
NETs. According to the ENETS 2016 Guidelines [15], SSA 
dose escalation may be recommended in refractory car-
cinoid syndrome or in the case of insufficient syndrome 
control for pancreatic NET [15]. SSAs may also be used for 
antiproliferative purposes in stable or progressive disease 
or in patients with unknown tumor behavior, and they are 
recommended as first line therapy in midgut NETs [15]. 
Lanreotide can be considered as first line therapy in 
pancreatic NETs with a Ki-67 proliferation index of up to 
10% [15]. While the antiproliferative efficacy of both lan-
reotide and octreotide is proven, there is a higher level 
of evidence for the use of lanreotide in pancreatic NETs. 
Octreotide is approved in Poland for tumor control in mid-
gut NETs, and lanreotide is approved for enteropancreatic 
NETs. SSAs may also be considered in low-grade NETs of 
other sites. 
While there is no established Ki-67 threshold for the 
use of SSAs, SSAs should preferably be used if Ki-67 is less 
than 10%. Initiation of therapy with a lower dose of the 
long-acting formulation or with subcutaneously injected 
octreotide at 50–100 µg for 7–10 days (two to three times 
per day) is recommended, particularly in patients with se-
vere symptoms [15].
Based on the results of the phase III, randomized, dou-
ble-blind, placebo-controlled CLARINET (Controlled study 
of Lanreotide Antiproliferative Response In NeuroEndo-
crine Tumors) study, the recommended dose of lanreotide 
Autogel is 120 mg every 28 days [19]. There is a consensus 
that an SSA such as lanreotide should be started at diag-
nosis in cases of high liver tumor burden and extended 
disease, since these are worse prognostic factors. Another 
factor favoring early SSA therapy is a primary pancreatic 
tumor, given that the overall 5-year survival rate in stage 
IV disease does not exceed 40–60% [19]. Currently, no data 
are available to support the continued use of SSAs when 
Table 1. Efficacy and safety of PRRT treatment 
Reference Treatment Number of 
NET patients 
in the study
Percentage of patients with controlled disease Percentage of patients with serious 
adverse events
Kwekkeboom  
et al. 2008 [11]
177Lu-
DOTA-TATE
310 Complete and partial tumor remissions occurred 
in 2% and 28% of patients, respectively; minor 
tumor response (decrease in size > 25% and  
< 50%) occurred in 16% of patients
0.97% with myelodysplastic 
syndrome; 0.65% with temporary, 
nonfatal, liver toxicity
Delpassand  
et al. 2014 [12]
177Lu-
DOTA-TATE
37 41% 22% with moderate (grade 2 or 3) 
bone marrow toxicity
Bushnell  
et al. 2010 [13]
90Y-DOTA-
TOC
90 74% 35.6% with serious adverse events; 
13.3% with gastrointestinal disorders
Imhof  
et al. 2011 [14]
90Y-DOTA-
TOC
1109 34.1% experienced morphologic response; 15.5% 
achieved biochemical response; and 29.7% 
showed clinical response
13% with hematologic toxicity (grade 
3 or 4); 9.2% with permanent renal 
toxicity (grade 4 or 5)
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patients progress on this therapy (an insight into the field 
will be brought by the results of the ongoing CLARINET 
FORTE study of patients with pancreatic or midgut NETs 
having progressed radiologically while previously treated 
with lanreotide Autogel 120 mg [20]); however, SSAs may 
be useful for continued suppression of functionally active 
tumors. Prospective clinical trials will further evaluate the 
role of SSAs (lanreotide Autogel 120 mg and pasireotide, 
respectively) in typical and atypical lung NETs. Although 
comprehensive clinical data are lacking for the use of SSAs 
in lung NETs, it is considered that the clinical behavior of 
typical carcinoids (mitotic count less than 2/10 high power 
fields [HPF]; NET G1) is similar to grade 1 NETs of other 
sites. Ongoing and planned clinical trials, including the 
SPINET study of lanreotide Autogel/Depot 120 mg [21], will 
further elucidate the role of SSAs in advanced lung NETs.
Other pharmacological treatments for 
gastroenteropancreatic neuroendocrine tumors
A second line therapy in functionally active GEP-NETs is 
interferon-α (IFN-α), which is recommended as an add-on 
therapy to SSA therapy in functioning tumors [15]. As men-
tioned above, traditional DNA-damaging cytotoxic drugs 
have limited efficacy in GEP-NET therapy. However, several 
proangiogenic molecules are overexpressed in NETs, such 
as vascular endothelial growth factor (VEGF) and its recep-
tors, epithelial growth factor receptor (EGFR), insulin-like 
growth factor 1 receptor (IGF-1R), phosphoinositide-3-ki-
nase (Pi3K), RAC-alpha serine/ threonine-protein kinase 
(AKT), and mammalian target of rapamycin (mTOR). There-
fore, drugs targeting some of these molecules are current-
ly under assessment in clinical trials, with some targeted 
compounds already recommended by ENETS for GEP-NET 
treatment [5,15]. 
An example of a targeted antiangiogenic therapy is ever-
olimus, a selective inhibitor of the mTOR signaling pathway, 
which disturbs translation and protein synthesis. In partic-
ular, everolimus decreases the concentration of VEGF and 
inhibits tumor angiogenesis [22]. It strongly inhibits the 
growth and proliferation of tumor cells, endothelial cells, 
fibroblasts, and vascular smooth muscle cells [22]. Accord-
ing to the ENETS 2016 Guidelines, everolimus can be rec-
ommended in the progression of advanced non-pancreatic 
GEP-NETs of intestinal or lung origin, or in midgut NETs as 
a second or third line therapy after failure of SSAs and/or 
IFN-α or PRRT [15]. This recommendation is based on the 
results of the phase III, randomized, double-blind, place-
bo-controlled, RADIANT-4 trial that demonstrated superior 
progression-free survival (PFS) with everolimus (n = 205) 
compared to placebo (n = 97) in patients with non-func-
tioning NETs of intestinal or lung origin (median PFS was 11 
months [95% CI: 9.2–13.3] vs. 3.9 months [95% CI: 3.6–7.4] 
in the active treatment and placebo groups, respectively) 
[15, 23]. This improvement in PFS was also observed in the 
phase III placebo-controlled RADIANT-2 trial, which investi-
gated the use of everolimus plus long-acting octreotide in 
advanced NETs associated with carcinoid syndrome [15, 24]. 
Everolimus is also currently recommended in the absence 
of approved drugs in metastatic lung NETs, as the first line 
therapy in progressive disease [15]. However, SSAs may also 
be considered first line therapy in patients with low prolif-
erative activity (grade 1, NETs) with strong SSTR expression 
on imaging [15]. 
Sunitinib is another medication used for GEP-NET ther-
apy. It inhibits multiple receptor tyrosine kinases (RTKs) 
that are implicated in tumor growth, neoangiogenesis, and 
metastatic progression of cancer. Sunitinib is an inhibitor 
of the platelet-derived growth factor receptors (PDGFRα 
and PDGFRβ), vascular endothelial growth factor receptors 
(VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor 
(KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulat-
ing factor receptor (CSF-1R), and the glial cell-line derived 
neurotrophic factor receptor (RET) [25]. According to the 
ENETS 2016 Guidelines, everolimus and sunitinib are ap-
proved antiproliferative therapies in progressive pancre-
atic NETs, and are recommended after failure of SSA or 
chemotherapy in pancreatic NETs [15]. There is a consen-
sus that targeted drugs should not be broadly used as the 
first line therapy due to their potential toxicity. However, 
targeted drugs can be considered as a first line therapy 
when SSA is not an option, and if systemic chemothera-
py is not clinically required, not feasible, or not tolerated 
[15]; however, sunitinib is currently not recommended in 
non-pancreatic NETs outside of clinical trials.
Combined SSA and targeted therapy in 
gastroenteropancreatic neuroendocrine tumors
It is a standard practice to combine targeted drugs with 
SSAs in functionally active NETs. Although there might 
be some rationale to also combining targeted drugs with 
SSAs in non-functioning NETs showing expression of 
SSTRs, there is no robust evidence yet that the combina-
tion therapy is superior to monotherapy with either evero-
limus or sunitinib for antiproliferative purposes. Therefore, 
combination therapy of targeted drugs with SSAs cannot 
be recommended in a first line setting in GEP-NETs in the 
absence of a comparative study of targeted drugs with 
either lanreotide or octreotide compared to the targeted 
drug alone. Furthermore, there are insufficient data to 
support the use of other targeted drugs (including bevaci-
zumab, sorafenib, pazopanib, or axitinib) in either pancre-
atic or non-pancreatic NETs. These drugs, as well as suni-
tinib in midgut NETs [26], are currently being explored in 
prospective randomized clinical trials, but the results have 
not been published yet. 
Lanreotide in gastroenteropancreatic 
neuroendocrine tumors therapy 
Lanreotide is an octapeptide analog of natural soma-
tostatin (SST). Like SST, lanreotide is an inhibitor of various 
endocrine, neuroendocrine, exocrine, and paracrine func-
tions. Lanreotide has a high affinity for human SSTR type 2 
and 5, and a reduced binding affinity for human SSTR1, 3, 
and 4 [27]. Lanreotide, like SST, exhibits a general exocrine 
anti-secretory action inhibiting the basal secretion of mo-
tilin, gastric inhibitory peptide and pancreatic polypeptide, 
but has no significant effect on fasting secretin or gastrin 
secretion [27]. Lanreotide is more active than natural SST, 
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with a much longer duration of action, and is classified as 
a long-acting SSA [27]. 
It is indicated to treat grade 1 and a subset of grade 2 
(i.e., those with a Ki-67 value less than 10%) GEP-NETs of 
the midgut, pancreas, or those of unknown origin where 
hindgut sites of origin have been excluded [15]. It is also 
recommended for the treatment of adult patients with un-
resectable locally advanced or metastatic disease. Another 
indication of lanreotide in GEP-NETs is in the treatment 
of symptoms associated with NETs, particularly NETs of 
the small intestine [15]. SSAs, including lanreotide, are rec-
ommended not only to treat symptoms, but also to attain 
tumor growth control [15]. The evidence for the indication 
to use lanreotide for antiproliferative effects was based on 
the CLARINET study [19] performed in over 200 patients 
with non-functioning enteropancreatic NETs and Ki-67 
values < 10%. Therapeutic goals of lanreotide treatment 
were antiproliferative action, control of hormonal symp-
toms, improvement in the QoL, decreased risk of compli-
cations, and possible increase in survival of patients with 
advanced NETs. PFS (primary endpoint) at 24 months was 
achieved in 65.1% (95% CI: 54.0–74.1) of patients treated 
with lanreotide Autogel 120 mg compared to 33% (95% CI: 
23.0–43.3) of patients in the placebo group [14]. Lanreotide 
Autogel 120 mg increased PFS in patients with midgut 
NETs (n = 73, p = 0.0091, HR = 0.35) and pancreatic NETs 
(n = 91, p = 0.0637, HR = 0.58) compared to placebo [14]. 
It also prolonged the time to disease progression or death 
in the treatment group of NETs with hepatic tumor load 
≤25% and > 25% (p = 0.0002, HR = 0.34 and p = 0.0170, 
HR = 0.45, respectively) compared to the corresponding 
placebo groups. 
The influence of the therapy on QoL is almost as im-
portant for patients as its efficacy and safety, especially 
during long-lasting treatment regimens. In the CLARINET 
study, the influence of lanreotide Autogel 120 mg treat-
ment on QoL was a secondary endpoint [19]. To stan-
dardize the assessment, patients in the treatment group 
and in the placebo group filled in the QLQ-C30 [28] and 
QLQ-GI. NET21 [29] questionnaires prepared by the Euro-
pean Organization for Research and Treatment of Cancer 
(EORTC). QLQ-C30 is composed of 30 detailed questions 
regarding QoL of patients with diverse tumors, which al-
lows the influence of disease symptoms’ severity and in-
troduced therapy on patients’ activity in everyday life to 
be analyzed (results range from 0 to 100). QLQ-GI.NET21 
is a set of 21 questions regarding health status, side ef-
fects of the treatment, disease-related fear, social life ac-
tivity, and problems with communication and sexual life. 
The CLARINET study focused on analyzing the influence of 
endocrine- and gastrointestinal-related symptoms on the 
QoL of patients with GEP-NET. Similar to the results of the 
QLQ-C30, results from the QLQ-GI.NET21 ranged from 0 to 
100, with lower scores indicating less severe symptoms. 
However, contrary to the QLQ-C30, higher total scores 
meant better QoL. Mean (standard deviation [SD]) basal 
values of QLQ-C30 scores were 70.2 (19.9) in the treat-
ment group and 73.6 (19.6) in the placebo group. At week 
48 and week 96 of therapy, the mean (SD) QLQ-C30 scores 
were 70.9 (17.3) versus 72.0 (14.9) and 66.4 (22.1) vs. 70.1 
(22.2) for the treatment and placebo groups, respectively, 
indicating that the QoL of patients was good in the two 
treatment groups [16, 23]. With regards to gastrointestinal 
symptoms, the mean (SD) basal values of QLQ-GI.NET21 
scores were 17.1 (16.4) in the group placebo vs. 18.3 (18.0) in 
the treatment group; these scores decreased to 15.3 (13.8) 
vs. 17.5 (17.4), respectively, after 96 weeks of therapy, indi-
cating that the severity of gastrointestinal symptoms was 
slightly decreased [19, 30].
In addition, adverse events (AEs) occurred in similar 
percentages of patients in the treatment and placebo 
group (88% vs. 90%, respectively). In the treatment group, 
50% of patients experienced any AE classified as treat-
ment-related compared to 28% of patients in the placebo 
group. Sixty-one patients experienced mild or moderate 
AEs both in the treatment and placebo group. Only three 
patients in the treatment group and one patient in the 
placebo group experienced at least one serious adverse 
event (SAE). There were seven SAEs (hyperglycemia, dia-
betes mellitus, nausea, vomiting, abdominal pain, biliary 
fistula, cholelithiasis) reported in the treatment group and 
one SAE (bile duct stenosis) in the placebo group. The most 
common treatment-related AEs were diarrhea, abdominal 
pain, and gallstones, occurring in 26%, 14%, and 10% of 
treatment group patients, respectively. Less than 10% of 
patients reported the following treatment-related AEs: 
flatulence, injection-site pain, nausea, vomiting, head-
ache, lethargy, hyperglycemia, or decreased level of pan-
creatic enzymes [19].
The results of the CLARINET study show that long-term 
treatment with lanreotide Autogel 120 mg administered 
every 28 days does not negatively influence the QoL of 
treated patients and that treatment-related AEs are usual-
ly mild or moderate. According to the 2015 National Com-
prehensive Cancer Network (NCCN) Guidelines, lanreotide 
is recommended in the treatment of patients with local 
GEP NETs and symptoms of excessive hormone secretion, 
in patients with GEP-NET metastases and carcinoid syn-
drome, and also in patients with tumors of clinically signif-
icant volume or with disease progression to decrease the 
tumor growth [31]. It is also considered in patients with 
diagnosed pancreatic NETs with hormonal symptoms, or 
without hormonal symptoms if the SSTR results are posi-
tive [31]. Lanreotide treatment can also be recommended 
in patients with non-resectable, asymptomatic, stable tu-
mors of low-volume or (besides other treatment options) 
in patients with non-resectable, high-volume pancreatic 
tumors or clinically significant disease progression [31]. 
According to the ENETS 2016 Guidelines, lanreotide is rec-
ommended as the first line therapy for the treatment of 
patients with grade 1 and grade 2 midgut and pancreatic 
NETs, with a low or high liver tumor burden [15]. Therapy 
recommendations according to ENETS 2016 [15] are sum-
marized in Table 2.
In conclusion, treatment of GEP-NETs is complex and 
should be individualized for each patient. A multidisci-
plinary approach is recommended to provide the patient 
with surgical treatment, pharmacological treatment (in-
cluding SSAs), radio- and chemotherapy, or combinations 
of the abovementioned, as needed. The role of psychoso-
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cial support for the patients and their families should also 
be treated as an important part of the therapeutic process.
Besides their role in inhibiting hormonal activity in GEP-
NETs, SSAs can influence the progression of NETs; indeed, 
the antiproliferative effects of lanreotide and octreotide 
were confirmed in midgut NETs. Lanreotide was also prov-
en to inhibit proliferation in pancreatic NETs and grade 1 
and grade 2 NETs of unspecified origin with Ki-61 values 
less than 10%, independent of the hepatic tumor load. 
These observations are now changing the therapeutic 
strategies used in patients with GEP-NETs towards active 
treatment with SSAs. In addition, ongoing studies inves-
tigating the action of SSAs in dual therapy with sunitinib 
or everolimus are expected to show promising results in 
terms of efficacy. Despite the recent data outlined in this 
review, further research is required to optimize the holistic 
treatment approach for GEP-NET patients. 
 The current review is the result of the expert meeting 
sponsored by Ipsen Poland. 
The authors declare no conflict of interest. 
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